Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Appoints Theresa Wingrove, Ph.D., as Vice President, Regulatory Affairs
WALTHAM, Mass., Jan 18, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the appointment of Theresa G.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2011 Financial Results
ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2011 Financial Results WALTHAM, Mass., Jan 20, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (NASDAQ:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise
View HTML
Toggle Summary ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2011 Financial Results
-Company Expects Significant Progress across a Number of Programs in 2011-
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 25, 2011
> WALTHAM, Mass., Feb 01, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, invites investors, journalists and the general public to
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass., Feb 08, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will present at two
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass.--( BUSINESS WIRE )-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Company management will participate in two
View HTML
Toggle Summary ImmunoGen, Inc. Announces Presentations at the 102nd Annual Meeting of the American Association for Cancer Research
WALTHAM, Mass., Mar 30, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that nine presentations - one oral and
View HTML
Toggle Summary ImmunoGen, Inc. Announces First Data for Its IMGN529 Product Candidate for Non-Hodgkin's Lymphoma
- Novel product candidate employs ImmunoGen's TAP technology with an antibody that has marked anticancer activity - can kill cancer cells via multiple mechanisms - On track for IND submission this summer
View HTML
Toggle Summary ImmunoGen, Inc. Announces First Data for its Novel Therapeutic for Ovarian Cancer and Other Carcinomas
-- Product candidate on track for IND submission within next twelve months -- AACR 2011 Program Committee grants special recognition to IMGN853 abstract
View HTML
Toggle Summary T-DM1 Significantly Improved Progression-Free Survival in Randomized Phase II Trial
WALTHAM, Mass., Apr 07, 2011 (BUSINESS WIRE) -- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine
View HTML